Keros Therapeutics, Inc.(KROS)

$11.19—Stale · unknown old

Ask SA Chart

Keros Therapeutics, Inc.(KROS)

NASDAQ • Last print unknown ago

$11.19—Stale · unknown old

Ask SA Chart Studio

KROS(KROS)

KROS

Next report

Nov 4 2026in 46 days

EPS estimate

($0.96)

Revenue estimate

$15M

EPS beats

7 of last 12

EPS surprise

Each report against the estimate that stood when it landed.

Nov 6 2023Aug 3 2026

Reported	EPS est	EPS actual	Surprise	Revenue est	Revenue actual	Surprise
Aug 3 2026	($1.34)	($1.45)	-8.2%	$807143	—	—
May 14 2026	($0.92)	($1.21)	-31.5%	$2M	$367000	-81.0%
Mar 4 2026	($0.49)	($0.86)	-75.5%	$4M	$385000	-89.5%
Nov 5 2025	($1.11)	($0.18)	+83.8%	$4M	$14M	+289.4%
Aug 6 2025	($1.14)	($0.76)	+33.3%	$3M	$18M	+465.9%
May 6 2025	($0.01)	$3.62	+36300.0%	$57M	$211M	+272.9%
Feb 26 2025	($1.36)	($1.14)	+16.2%	$22M	$3M	-86.3%
Nov 6 2024	($1.26)	($1.41)	-11.9%	$2M	$388000	-83.2%
Aug 7 2024	($1.23)	($1.25)	-1.6%	—	$37000	—
May 8 2024	($1.31)	($1.21)	+7.6%	—	$83000	—
Feb 28 2024	($1.38)	($1.34)	+2.9%	—	$143000	—
Nov 6 2023	($1.34)	($1.33)	+0.7%	—	$8000	—

Earnings & Revenue Estimates

Earnings Call Transcripts

No earnings transcripts available for KROS

Transcripts may not be available for all companies

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance

Reported

EPS est

EPS actual

Surprise

Revenue est

Revenue actual

Surprise

Aug 3 2026

($1.34)

($1.45)

-8.2%

$807143

—

May 14 2026

($0.92)

($1.21)

-31.5%

$2M

$367000

-81.0%

Mar 4 2026

($0.49)

($0.86)

-75.5%

$4M

$385000

-89.5%

Nov 5 2025

($1.11)

($0.18)

+83.8%

$4M

$14M

+289.4%

Aug 6 2025

($1.14)

($0.76)

+33.3%

$3M

$18M

+465.9%

May 6 2025

($0.01)

$3.62

+36300.0%

$57M

$211M

+272.9%

Feb 26 2025

($1.36)

($1.14)

+16.2%

$22M

$3M

-86.3%

Nov 6 2024

($1.26)

($1.41)

-11.9%

$2M

$388000

-83.2%

Aug 7 2024

($1.23)

($1.25)

-1.6%

—

$37000

—

May 8 2024

($1.31)

($1.21)

+7.6%

—

$83000

—

Feb 28 2024

($1.38)

($1.34)

+2.9%

—

$143000

—

Nov 6 2023

($1.34)

($1.33)

+0.7%

—

$8000

—

Metric

FY2026E

FY2027E

FY2028E

FY2029E

FY2030E

Revenue Avg

$16M

$14M

$45M

$75M

$127M

Low

$1M

$9M

$45M

$7M

$11M

High

$23M

$18M

$45M

$102M

$173M

EBITDA Avg

$-207M

$-233M

$-144M

$-1.44B

$-43M

Low

$-233M

$-327M

$-340M

$-2.12B

$-71M

High

$-182M

$-139M

$-73M

$345M

$29M

EBIT Avg

$-209M

$-236M

$-149M

$-1.45B

$-59M

Low

$-235M

$-330M

$-345M

$-2.13B

$-86M

High

$-184M

$-142M

$-78M

$336M

$14M

Net Income Avg

$-209M

$-236M

$-149M

$-1.45B

$-59M

Low

$-235M

$-330M

$-345M

$-2.13B

$-86M

High

$-184M

$-142M

$-78M

$265M

$11M

EPS Avg

$-5.54

$-6.24

$-4.66

$-38.39

$-1.55

Low

$-6.20

$-8.71

$-9.12

$-56.16

$-2.26

High

$-4.85

$-3.75

$-2.07

$7.01

$0.28

Analysts (Rev / EPS)

5 / 5

6 / 6

4 / 3

3 / 2

Metric

Q3 2026

Q4 2026

Q1 2027

Q2 2027

Q3 2027

Q4 2027

Q1 2028

Q2 2028

Revenue Avg

$15M

$478,571

$433,333

—

Low

$384,200

$23,522

$21,298

—

High

$22M

$683,832

$619,191

—

EBITDA Avg

$-18M

$-38M

$-44M

$-32M

$-34M

$-35M

—

Low

$-26M

$-43M

$-68M

$-50M

$-53M

$-55M

—

High

$-11M

$-33M

$14M

$10M

$11M

—

EBIT Avg

$-19M

$-38M

$-44M

$-33M

$-35M

$-36M

—

Low

$-27M

$-44M

$-69M

$-51M

$-54M

$-56M

—

High

$-12M

$-33M

$13M

$10M

$11M

—

Net Income Avg

$-19M

$-38M

$-44M

$-33M

$-35M

$-36M

$-44M

$-45M

Low

$-27M

$-44M

$-69M

$-51M

$-54M

$-56M

$-69M

$-70M

High

$-12M

$-33M

$10M

$8M

$10M

$11M

EPS Avg

$-0.94

$-1.93

$-2.23

$-1.65

$-1.75

$-1.81

$-2.23

$-2.26

Low

$-1.37

$-2.21

$-3.47

$-2.57

$-2.73

$-2.82

$-3.47

$-3.52

High

$-0.58

$-1.67

$0.53

$0.39

$0.41

$0.43

$0.53

Analysts (Rev / EPS)

4 / 4

2 / 1

— / 2